Avara Pharmaceutical Services, an international pharmaceutical services company, has signed an agreement with AstraZeneca to acquire its Reims, France manufacturing and distribution facility.
 
“This key acquisition is another important component of our strategic plan that further expands our services,” said Timothy C. Tyson, Chairman and CEO.
 
Avara provides both API formulation and manufacturing, along with secondary formulation, manufacturing, packaging and distribution of small molecule drugs, including highly potent compounds. Avara has secondary manufacturing technologies including granulation, coating, blending, encapsulation, compression and drying of tablets and capsules. Avara also has secondary sterile manufacturing capability in the Liscate site. 
Together with the Reims facility, Avara now has eight sites: three in the U.S., including the corporate HQ’s; one in Puerto Rico; one in the UK; one in Ireland; one in Italy and this new additional site in France. 
“With rapid expansion and integration set for 2017-2018, we continue, with great confidence, to build a pharmaceutical services company with complementary offerings in key regions to serve the rapidly growing market. Each site has significant professional experience, state of the art capability and a long history of delivering high quality pharmaceuticals that meet or exceed customer expectations and regulatory requirements in every major market around the world. The people who are a part of the Avara team are the key to our long-term success,” said Mr. Tyson.